Chief Executive Officer
CurrentAIQ is changing how clinicians manage complex diseases, starting with late-stage cancer. AIQ develops novel imaging biomarkers that assess and predict a patient’s response to treatment, including both effectiveness and toxicity. The biomarkers provide more comprehensive and accurate information about treatment response than other approaches. Oncologists use AIQ’s technology to make more confident treatment decisions, personalize care for their patients, and improve treatment outcomes. Including future expansion into other diseases, such as neurology and cardiology, the global market opportunity is forecast to exceed $30B by 2027. AIQ’s products are cloud-architected software solutions. The company has offices in Madison, Wisconsin, and Perth, Australia.